Shahid Ashfaque

821 total citations · 1 hit paper
7 papers, 107 citations indexed

About

Shahid Ashfaque is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Shahid Ashfaque has authored 7 papers receiving a total of 107 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Shahid Ashfaque's work include Cancer Treatment and Pharmacology (6 papers), HER2/EGFR in Cancer Research (4 papers) and Breast Cancer Treatment Studies (4 papers). Shahid Ashfaque is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), HER2/EGFR in Cancer Research (4 papers) and Breast Cancer Treatment Studies (4 papers). Shahid Ashfaque collaborates with scholars based in Japan, United States and South Korea. Shahid Ashfaque's co-authors include Wěi Li, Anton Egorov, Javier Cortés, Joanne Chiu, Giuseppe Curigliano, Seock‐Ah Im, Giampaolo Bianchini, Sung‐Bae Kim, Sara A. Hurvitz and Xian Wang and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Shahid Ashfaque

7 papers receiving 106 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

2024 53 citations Javier Cortés, Sara A. Hurvitz et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shahid Ashfaque Japan	5	92	54	22	18	8	7	107
Cornelia Kolberg‐Liedtke Germany	5	64 0.7×	33 0.6×	15 0.7×	52 2.9×	8 1.0×	20	90
Bronwyn D. Mixter United States	4	70 0.8×	34 0.6×	9 0.4×	30 1.7×	18 2.3×	5	100
Shrushma Loi United Kingdom	6	117 1.3×	36 0.7×	39 1.8×	40 2.2×	6 0.8×	11	122
Cristina Viaplana Spain	5	64 0.7×	34 0.6×	15 0.7×	16 0.9×	7 0.9×	19	82
Sandeep H. Mashru United States	4	71 0.8×	55 1.0×	9 0.4×	21 1.2×	26 3.3×	7	96
Qilong Zhang China	4	41 0.4×	29 0.5×	11 0.5×	14 0.8×	10 1.3×	9	50
Scott Hofsess United States	4	125 1.4×	46 0.9×	61 2.8×	21 1.2×	28 3.5×	5	149
Samuel M. Niman United States	5	56 0.6×	24 0.4×	9 0.4×	40 2.2×	16 2.0×	15	76
Manuel Ruíz-Borrego Spain	4	60 0.7×	43 0.8×	6 0.3×	31 1.7×	11 1.4×	9	79
Jagdish Shetty United States	4	79 0.9×	40 0.7×	13 0.6×	12 0.7×	6 0.8×	7	89

Countries citing papers authored by Shahid Ashfaque

Since Specialization

Citations

This map shows the geographic impact of Shahid Ashfaque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shahid Ashfaque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shahid Ashfaque more than expected).

Fields of papers citing papers by Shahid Ashfaque

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shahid Ashfaque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shahid Ashfaque. The network helps show where Shahid Ashfaque may publish in the future.

Co-authorship network of co-authors of Shahid Ashfaque

This figure shows the co-authorship network connecting the top 25 collaborators of Shahid Ashfaque. A scholar is included among the top collaborators of Shahid Ashfaque based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shahid Ashfaque. Shahid Ashfaque is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Hamilton, Erika, Sara A. Hurvitz, Seock‐Ah Im, et al.. (2024). Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03.. Journal of Clinical Oncology. 42(16_suppl). 1025–1025. 5 indexed citations

2.

Cortés, Javier, Sara A. Hurvitz, Seock‐Ah Im, et al.. (2024). Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nature Medicine. 30(8). 2208–2215. 53 indexed citations breakdown →

3.

Yamashita, Toshinari, Baojun Xu, Hitoshi Iwata, et al.. (2024). 186P Exploratory pooled safety analysis of trastuzumab deruxtecan (T-DXd) in patients With HER2+ or HER2-low unresectable and/or metastatic breast cancer (mBC) in DESTINY-Breast trials. ESMO Open. 9. 103208–103208. 2 indexed citations

4.

André, Fabrice, Javier Cortés, Wěi Li, et al.. (2024). A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases. Annals of Oncology. 35(12). 1169–1180. 15 indexed citations

5.

Kim, S-B., Fabrice André, Toshimi Takano, et al.. (2024). 182MO Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2+ metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1): Updated overall survival (OS) results of the randomized phase III DESTINY-breast (DB-)02 study. ESMO Open. 9. 103204–103204. 1 indexed citations

6.

Modi, Shanu, Wěi Li, Y.H. Park, et al.. (2023). 377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. Annals of Oncology. 34. S335–S336. 24 indexed citations

7.

Hurvitz, Sara A., Roberto Hegg, Wei‐Pang Chung, et al.. (2023). Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03. Cancer Research. 83(5_Supplement). GS2–2. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact